Skip to main content
. 2022 Feb 18;10(2):486. doi: 10.3390/biomedicines10020486

Figure 7.

Figure 7

Schematic representation of in vivo targeting with nanocarrier DTIC@HMLBFs. First, by EPR effect, the nanocarrier can achieve the tumor tissue, with higher local accumulation, and then target folate-receptors of melanoma cells and tumor-associated macrophage (TAM). Reprinted from [56] with permission from American Chemical Society, 2021.